Phase 2 Peripheral Neuropathy Trial, Recruiting NCT06848348 Sponsor: Dogwood Therapeutics Inc. Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 2 Peripheral Neuropathy Trial, Recruiting

NCT06848348
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any gender.
  • People whose nerve pain has been present and is linked to chemotherapy treatment involving platinum-based drugs, taxane-based drugs, or both.
  • People who have completed a chemotherapy treatment that included taxane or platinum drugs, and whose cancer is not currently showing signs of getting worse or spreading.

Who may not be able to join:

  • People whose nerve pain symptoms are similar to chemotherapy-related nerve pain but are caused by something other than platinum or taxane chemotherapy.
  • People who have received a treatment called HAL at any point before the screening stage of this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 866-620-9255

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Dogwood Therapeutics Inc.
Registry
ClinicalTrials.gov
Start date
21 February 2025
Est. completion
1 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

NRS Pain; Safety Assessments

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov